FDA Establishes Biosmilar Naming Convention

September 1, 2015

Last week, FDA announced the highly anticipated guidance, along with a proposed rule, which will establish a naming convention for biological products, including both related and biosimilar products. FDA states that a “shared proprietary names are not appropriate for all biological products.” In addition, the Agency says that, for both pharmacovigilance and safe use purposes, there is a large need to clearly identify different biological products that have not been identified as interchangeable.

According to FDA’s plan, both branded and biosimilar products will share what they call a “core drug substance” name. In addition, each product will also have a suffix that will be made up of four letters. The suffixes will not be derived from the manufacturers name and will be individualized from product to product.

FDA is asking for feedback from industry professionals on their new guidance and proposed rule. Comments are currently being submitted here, and are being accepted until October 27, 2015 on the guidance, and until November 12, 2015 on the rule.

For the last 35 years, we have been helping our clients achieve successful interactions with the FDA and have established a strong relationship with the Agency over the years.  We have the knowledge and experience you need to develop and submit a successful application.  Contact us today to learn more about our services and how we can help you.



Agency Alerts

September 1, 2015

FDA Updates Guidelines for Biosimilar Naming Convention

On August 28, 2015, FDA announced the availability of a draft guidance, entitled “Nonproprietary Naming of Biological Products,” which established a naming convention for biological products.  The...

Read More
Clinical Research Solutions

September 1, 2015

6 Compliance Tips to get FDA Approval for Your Pharmaceutical Project

Overview: the FDA Approval Process   The Food and Drug Administration (FDA), as part of the United States (US) Department of Health and Human Services, is the regulatory agency responsible for the...

Read More
Agency Alerts General Regulatory

September 1, 2015

What to Expect During the NDA Review Process

Compiling and submitting an NDA is a complicated and intensive activity. Once you have submitted your application to FDA, you may be curious about what can you expect to hear and when. Below are some...

Read More